The US Food and Drug Administration (FDA) has approved tezepelumab-ekko (Tezspire) as a first in class treatment for severe asthma in adults and pediatric patients aged 12 years and older. It is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback